Dergiler / Annals of Medical Sciences / 2001 / Cilt: 10 - Sayı: 1

TNF-$alpha$ and IL-1$beta$ levels in serum and cerebrospinal fluid in patients with multiple sclerosis

Sayfa
20–24
Yayın Tarihi
2022-10-10
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: These data provide evidence that TNF-$alpha$ and IL-1$beta$ levels in CSF can be used as an activity criteria in MS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Purpose: Proinflammatory cytokines like tumor necrosis factor-alpha (TNF-$alpha$ ) and interleukin-1beta (IL-1ß ) enhance inflammation and may contribute to the pathogenesis of multiple sclerosis.
📊
Temel Bulgular & Veri:Methods: We measured TNF-$alpha$ and IL-1$beta$ levels in cerebrospinal fluid (CSF) and serum samples from 22 patients with MS and 18 patients with other neurological diseases (OND) using commercially available immunoradiometric assay kits.
💡
Sonuç & Katkı:Conclusion: These data provide evidence that TNF-$alpha$ and IL-1$beta$ levels in CSF can be used as an activity criteria in MS.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Purpose: Proinflammatory cytokines like tumor necrosis factor-alpha (TNF-$alpha$ ) and interleukin-1beta (IL-1ß ) enhance inflammation and may contribute to the pathogenesis of multiple sclerosis. The purpose of this study is to investigate the presence of these cytokines in multiple sclerosis (MS) patients with different clinical types and disease activity, and to determine their relationship with disability. Methods: We measured TNF-$alpha$ and IL-1$beta$ levels in cerebrospinal fluid (CSF) and serum samples from 22 patients with MS and 18 patients with other neurological diseases (OND) using commercially available immunoradiometric assay kits. Results: In serum, TNF-$alpha$ was detected in all patients, IL-1$beta$ was detected in 20 patients with MS and in 16 patients with OND. In CSF, all patients had detectable levels of both cytokines. The serum cytokine levels of patients with MS and patients with OND were not statistically different. However, in CSF, regardless of the clinical type, patients with active MS had higher levels of both cytokines compared to patients with stable MS and OND. There was no correlation between the levels of these cytokines and the disability. Conclusion: These data provide evidence that TNF-$alpha$ and IL-1$beta$ levels in CSF can be used as an activity criteria in MS.

🔖

Bu Makaleye Atıf Yap

DEMİRKIRAN, M., GÜNEŞAÇAR, R., ERKEN, E., SARICA, Y. (2022). TNF-$alpha$ and IL-1$beta$ levels in serum and cerebrospinal fluid in patients with multiple sclerosis. Annals of Medical Sciences, Cilt: 10 - Sayı: 1, 20–24. https://ajindex.com/articles/447453

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Woodroofe MN: Cytokine production in the central nervous system. Neurology 1995;45(suppl 6):S6-S10
  2. Carrieri PB: The role of cytokines in the pathogenesis of multiple sclerosis. Int MSJ 1994;1:53-59
  3. Arnason B: The role of cytokines in multiple sclerosis. Neurology 1995;45 (suppll):S54-S55
  4. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-346
  5. Giulian D, Lachman LB. Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 1985;228:497-499
  6. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Siberberg DH, Tourtellotte WW: New diagnostic critria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
  7. Gallo P, Piccinno MG, Pagni S, Argentiero V, Giom etto B, Bozza F, Tavolato B: Immune activation in multiple sclerosis: study of IL-2, sIL-2r and gamma IFN levels in serum and cerebrospinal fluid. J Neurol Sci 1989;92:9-15
  8. Peter JB, Boctor FN, Tourtellotte WW: Serum and CSF levels of IL-2, sIL-2R, TNF-α, IL-1ß in chronic progressive multiple sclerosis. Expected lack of clini cal utility. Neurology 1991;41:121-123
  9. Franciotta DM, Grimaldi LME, Martino GV, Piccolo G, Bergamaschi R, Citterio A, Melzi d'Eril CV: Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 1989;26:787-789
  10. Maimone D, Gregory S, Arnason BGW, Reder AT:Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991;32:67-74
  11. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K: Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 1991;102:230-234
  12. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA: Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 1990;40:1735-1739
  13. Sharief MK, Hentges R: Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Eng J Med 1991;325:467- 472
  14. Trotter JL, Kollins KG, van der Veen RC: Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-α levels. J Neuroimmunol 1991;33:29-36
  15. Drukovic J, Mostarica-Stojkovic M, Levic Z, Stojsavljevic N, Provica V, Mesaros S. Interleukin-12 and TNF-